AbbVie's Upadacitinib shows long-term, sustained efficacy in atopic dermatitis

AbbVie has released long-term efficacy and safety data from three studies of upadacitinib in moderate to severe atopic dermatitis. Analysis of 140-week data from Measure Up1 (NCT03569293), Measure Up2 (NCT03607422) and AD Up (NCT03568318) showed that patients treated with 15mg and 30mg achieved significantly higher skin clearance rates compared with placebo. Improvement in skin clearance was measured by Eczema Area and Severity Index 75 (EASI 75) and Validated Investigator Atopic Dermatitis Global Assessment 0 or 1 (vIGA-AD 0/1).

Of the three trials, patients treated with the 30 mg dose achieved the highest improvements in EASI 75 and vIGA-AD 0/1 at week 140. Participants treated with the 30 mg dose in the Measure Up2 trial achieved the greatest EASI75 improvement (90.7%), while the highest vIGA-AD 0/1 improvement (65.5%) was observed in the 30 mg cohort in the Measure Up1 trial. Patients treated with upadacitinib also achieved greater pruritus reduction (WP-NRS 0/1), an additional endpoint compared with the placebo cohort.

People with moderate to severe atopic dermatitis often face persistent itching and inflammatory skin symptoms that interfere with their daily lives. These results reinforce our commitment to providing effective long-term treatment options for people with this debilitating disease and other chronic immune-mediated diseases. Upadatinib at 15 mg and 30 mg doses was well tolerated, and its safety profile was consistent with previous studies. New data analysis suggests that long-term continued use of upadatinib as a treatment for atopic dermatitis has "acceptable benefits and risks."